---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-315074"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:30.522977+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026

## Summary
- Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.
- Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.
- Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.
- Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.
- Saha resignation not due to any disagreement with company's operations or policies.

## SEC filing metadata
- accession: 0001193125-25-315074
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/0001193125-25-315074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/d933269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-315074
- JSON: https://secwatch.observer/filing/0001193125-25-315074.json
- Plain text: https://secwatch.observer/filing/0001193125-25-315074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.